Jan 20 (Reuters) - AstraZeneca  on Tuesday said it would delist its American Depositary Shares and debt securities from ‌Nasdaq and complete a direct listing ​of its ordinary shares and ‍debt on the New ⁠York Stock ⁠Exchange, effective after market close on ‌January 30, 2026.

The ​ordinary shares and debt securities are expected to ⁠commence trading on ‍the ​NYSE from February 2, with AstraZeneca maintaining its "AZN" ticker symbol.

The ‍move is part of a shareholder-approved plan to unify the company's share listing structure, allowing investors to trade its ​ordinary ‍shares across the London Stock Exchange, Nasdaq Stockholm ​and the NYSE.

Following implementation of the harmonised structure, AstraZeneca will shift from trading ADSs - which represent ordinary shares on a two-for-one basis - ​to a direct listing of its $0.25 ordinary shares, simplifying its multi-market trading ‍setup.